ArticleScientific reports2025
Pregnane X receptor (PXR) as a prognostic marker and therapeutic target in kidney renal clear cell carcinoma (KIRC) via AMPK pathway regulation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Kidney renal clear cell carcinoma (KIRC) is the most common histological subtype of renal cell carcinoma (RCC), characterized by high metastatic potential and mortality, accounting for over 75% of RCC patients worldwide. However, KIRC patients often exhibit poor prognosis due to the absence of effective and sensitive biomarkers for early detection. As a key xenobiotic and endobiotic receptor in humans, the pregnane X receptor (PXR, NR1I2) exerts regulatory functions on various biological signaling pathways—most of which are associated with tumorigenesis. In this study, we aimed to elucidate the role of PXR in KIRC and investigate its underlying mechanisms. Using The Cancer Genome Atlas (TCGA) database and our clinical KIRC samples, we analyzed the expression profile and prognostic value of PXR. Results showed that PXR was significantly upregulated in KIRC tumor tissues, and high PXR levels were associated with poor overall survival in KIRC patients. Further in vitro experiments demonstrated that modulating PXR markedly influenced KIRC cell proliferation, invasion, migration, and metastasis. RNA sequencing revealed that PXR knockdown in KIRC cells perturbed multiple cell signaling pathways. Mechanistic investigations showed that PXR down-regulation promoted the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway and affected the proliferation, apoptosis and invasion of KIRC cells. Our findings indicate that PXR is consistently upregulated in KIRC tissues and correlates with poor patient prognosis, suggesting it could serve as a potential biomarker for the diagnosis and prognosis of KIRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.